Canada markets close in 3 hours 38 minutes

Canntab Therapeutics Limited (TBF1.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
0.4820+0.0200 (+4.33%)
As of 8:00AM CEST. Market open.
Full screen
Previous Close0.4620
Open0.4820
Bid0.4660 x 0
Ask0.4900 x 0
Day's Range0.4820 - 0.4820
52 Week Range0.3780 - 0.7250
Volume2,500
Avg. Volume810
Market Cap17.15M
Beta (5Y Monthly)1.28
PE Ratio (TTM)N/A
EPS (TTM)-0.0590
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • CNW Group

    Canntab Announces the Early Exercise of $1,259,250 Warrants

    Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the "Company" or "Canntab"), the leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce the receipt of C$1,259,250 in gross proceeds from the early exercise of 1,679,000 warrants into common shares (the "Warrants"). The Warrants were issued in the final week of May and each Warrant was exercised into 1 common share in the capital of the Company at $0.75. T

  • CNW Group

    Canntab Mourns the Loss of Co-Founder

    Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the "Company" or "Canntab"), a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, announces, with very heavy hearts, the passing of Jeffrey Ward Renwick, the Company's Co-Founder, Director and President. After a long and difficult 15 month battle, Jeff succumbed to his lung cancer at the young age of 54 years.

  • CNW Group

    Canntab Receives Export License Approval from Health Canada

    Canntab Therapeutics Limited (CSE: PILL.CN) (OTCQB: CTABF) (FRA: TBF1.F) (the "Company" or "Canntab"), a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is pleased to announce that Health Canada has granted the company an Export License.